Molecular Cytogenetics Group, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid 28029, Spain; Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Barcelona 08036, Spain.
Molecular Cytogenetics Group, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid 28029, Spain.
Stem Cell Reports. 2017 May 9;8(5):1408-1420. doi: 10.1016/j.stemcr.2017.04.014.
Efficient methodologies for recreating cancer-associated chromosome translocations are in high demand as tools for investigating how such events initiate cancer. The CRISPR/Cas9 system has been used to reconstruct the genetics of these complex rearrangements at native loci while maintaining the architecture and regulatory elements. However, the CRISPR system remains inefficient in human stem cells. Here, we compared three strategies aimed at enhancing the efficiency of the CRISPR-mediated t(11;22) translocation in human stem cells, including mesenchymal and induced pluripotent stem cells: (1) using end-joining DNA processing factors involved in repair mechanisms, or (2) ssODNs to guide the ligation of the double-strand break ends generated by CRISPR/Cas9; and (3) all-in-one plasmid or ribonucleoprotein complex-based approaches. We report that the generation of targeted t(11;22) is significantly increased by using a combination of ribonucleoprotein complexes and ssODNs. The CRISPR/Cas9-mediated generation of targeted t(11;22) in human stem cells opens up new avenues in modeling Ewing sarcoma.
高效的方法可用于重现与癌症相关的染色体易位,这是研究此类事件如何引发癌症的工具。CRISPR/Cas9 系统已被用于在保持结构和调控元件的情况下,在天然基因座重建这些复杂重排的遗传学特征。然而,CRISPR 系统在人类干细胞中的效率仍然较低。在这里,我们比较了三种旨在提高 CRISPR 介导的人类干细胞中 t(11;22)易位效率的策略,包括间充质和诱导多能干细胞:(1) 使用涉及修复机制的末端连接 DNA 加工因子,或 (2)ssODN 引导 CRISPR/Cas9 产生的双链断裂末端的连接;和 (3) 基于单一体或核糖核蛋白复合物的方法。我们报告说,使用核糖核蛋白复合物和 ssODN 的组合可显著增加靶向 t(11;22)的产生。CRISPR/Cas9 介导的人类干细胞中靶向 t(11;22)的产生为建模尤文肉瘤开辟了新途径。